hydralazine has been researched along with Genetic Predisposition in 10 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo." | 3.71 | Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, Y | 1 |
| Sawalha, AH | 1 |
| Rame, JE | 1 |
| Tam, SW | 1 |
| McNamara, D | 1 |
| Worcel, M | 1 |
| Sabolinski, ML | 1 |
| Wu, AH | 1 |
| Dries, DL | 1 |
| Leelahavanichkul, A | 1 |
| Yan, Q | 1 |
| Hu, X | 1 |
| Eisner, C | 1 |
| Huang, Y | 1 |
| Chen, R | 1 |
| Mizel, D | 1 |
| Zhou, H | 1 |
| Wright, EC | 1 |
| Kopp, JB | 1 |
| Schnermann, J | 1 |
| Yuen, PS | 1 |
| Star, RA | 1 |
| Wassmann, S | 1 |
| Czech, T | 1 |
| van Eickels, M | 1 |
| Fleming, I | 1 |
| Böhm, M | 1 |
| Nickenig, G | 1 |
| Puckrein, G | 1 |
| Yancy, CW | 2 |
| Echols, MR | 1 |
| Hoover, EL | 1 |
| Sade, RM | 1 |
| Nakaya, H | 1 |
| Sasamura, H | 1 |
| Hayashi, M | 1 |
| Saruta, T | 1 |
2 reviews available for hydralazine and Genetic Predisposition
| Article | Year |
|---|---|
Drug-induced lupus erythematosus: an update on drugs and mechanisms.
Topics: Autoimmunity; Genetic Predisposition to Disease; Humans; Hydralazine; Immunologic Factors; Lupus Ery | 2018 |
Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure.
Topics: Black or African American; Disease Progression; Drug Combinations; Endothelium, Vascular; Genetic Pr | 2006 |
8 other studies available for hydralazine and Genetic Predisposition
| Article | Year |
|---|---|
Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy.
Topics: Black or African American; Cardiovascular Agents; Double-Blind Method; Drug Combinations; Female; Ge | 2009 |
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertens | 2010 |
Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Diseases; Apolipoproteins E; Arterioscleros | 2004 |
Illuminating BiDil.
Topics: Black or African American; Drug Approval; Drug Combinations; Genetic Predisposition to Disease; Hear | 2005 |
BiDil's impact.
Topics: Black or African American; Drug Approval; Drug Combinations; Genetic Predisposition to Disease; Hear | 2005 |
There is no scientific rationale for race-based research.
Topics: Biomarkers; Biomedical Research; Black or African American; Clinical Trials as Topic; Drug Combinati | 2007 |
What's right (and wrong) with racially stratified research and therapies.
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biomedical Research; Black or African American | 2007 |
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten | 2001 |